Hypolipidemic and Hepatoprotective Effects of a Polyprenol-Containing Drug in Patients with Acute Coronary Syndrome
- 作者: Vyshlov E.1, Tsoy E1, Sultanov V.2, Trusov V.3, Ryabov V.1
-
隶属关系:
- Cardiology Research Institute, Tomsk National Research Medical Center
- Prenolica Limited
- Solagift Company
- 期: 卷 165, 编号 3 (2018)
- 页面: 319-321
- 栏目: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/240262
- DOI: https://doi.org/10.1007/s10517-018-4159-x
- ID: 240262
如何引用文章
详细
In a double-blind placebo-controlled trial POLYNCOR (registration No. NCT03122340 at clinicaltrials.gov), lipid-lowering and hepatoprotective effects of polyprenol-containing drug Ropren were evaluated in patients with acute coronary syndrome. After 2-months therapy, total cholesterol and ALT in the patients receiving Ropren were significantly (p<0.05) lower than in the control group. The number of patients who needed to discontinue or reduce the dose of atorvastatin due to an increase in the level of transaminases in the main group was significantly (p<0.05) lower than in the control group: 0 (0%) vs. 5 (33.3%). The more pronounced decrease in cholesterol level and hepatoprotective effect of Ropren allowed recommending this preparation to patients with acute coronary syndrome in addition to standard therapy.
作者简介
E. Vyshlov
Cardiology Research Institute, Tomsk National Research Medical Center
编辑信件的主要联系方式.
Email: evv@cardio-tomsk.ru
俄罗斯联邦, Tomsk
E Tsoy
Cardiology Research Institute, Tomsk National Research Medical Center
Email: evv@cardio-tomsk.ru
俄罗斯联邦, Tomsk
V. Sultanov
Prenolica Limited
Email: evv@cardio-tomsk.ru
澳大利亚, Melbourne
V. Trusov
Solagift Company
Email: evv@cardio-tomsk.ru
俄罗斯联邦, Tomsk
V. Ryabov
Cardiology Research Institute, Tomsk National Research Medical Center
Email: evv@cardio-tomsk.ru
俄罗斯联邦, Tomsk
![](/img/style/loading.gif)